Arundic acid

DB05343InvestigationalSmall molecule

Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Mechanism: ONO-256 is a neuroprotective because of its actions on glia cells. It has inhibitory effects on the synthesis of a calcium-binding protein S100B. ONO-2506 is undergoing clinical trials for the treatment of patients with stroke and Alzheimer's disease.
Curator reviewed
Primary indication: Investigated for use/treatment in cerebral ischemia.Curator reviewed
Formula / weight: C₁₁H₂₂O₂ · 186.2912 g/mol (avg)
Code names: MK-0724 · ONO-2506PO

Resolves to

Compound

Structure

InChIKeyYCYMCMYLORLIJX-SNVBAGLBSA-NSMILESCCCCCC[C@@H](CCC)C(O)=O

Targets

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Arundic acid, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.